Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 19/20 | 0.85 |
| ▸ | EGFR | P00533 | 1/20 | 0.69 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.69 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.69 |
| ▸ | KDR | P35968 | 1/20 | 0.69 |
| ▸ | TEC | P42680 | 1/20 | 0.69 |
| ▸ | TXK | P42681 | 1/20 | 0.69 |
| ▸ | BLK | P51451 | 1/20 | 0.69 |
| ▸ | BMX | P51813 | 1/20 | 0.69 |
| ▸ | JAK3 | P52333 | 1/20 | 0.69 |
| ▸ | ITK | Q08881 | 1/20 | 0.69 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.69 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.69 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14630530 | 0.99 | BTK (0.87) | BTKEGFRERBB2ADORA3PTGS2 | |
| SCHEMBL14631282 | 0.92 | BTK (1.00) | BTK | |
| SCHEMBL14631277 | 0.92 | BTK (1.00) | BTK | |
| SCHEMBL14630994 | 0.91 | BTK (1.00) | BTK | |
| SCHEMBL14647398 | 0.91 | BTK (0.82) | BTKEGFRERBB2ADORA3PTGS2 | |
| SCHEMBL14631224 | 0.91 | BTK (0.76) | BTKEGFRERBB2ADORA3PTGS2 | |
| SCHEMBL14631218 | 0.91 | BTK (0.76) | BTKEGFRERBB2ADORA3PTGS2 | |
| SCHEMBL14630055 | 0.89 | BTK (0.78) | BTKEGFRERBB2ADORA3PTGS2 | |
| SCHEMBL14630060 | 0.89 | BTK (0.78) | BTKEGFRERBB2ADORA3PTGS2 | |
| SCHEMBL14631173 | 0.89 | BTK (0.78) | BTKEGFRERBB2ADORA3PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9758524-B2 | 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors | MERCK SHARP & DOHME B.V. (NL) | 2017-09-12 | — | — | US | disclosed |
| US-20160159810-A1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AND 4-IMIDAZOTRIAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS | MERCK SHARP & DOHME B.V. (NL) | 2016-06-09 | — | — | US | disclosed |
| US-20160151364-A1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AND 4-IMIDAZOTRIAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS | MERCK SHARP & DOHME B.V. (NL) | 2016-06-02 | — | — | US | disclosed |
| US-9290504-B2 | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors | MERCK SHARP & DOHME B.V. (NL) | 2016-03-22 | — | — | US | disclosed |
| US-20140155385-A1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AND 4-IMIDAZOTRIAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS | MERCK SHARP & DOHME B.V. (NL) | 2014-06-05 | — | — | US | disclosed |
| EP-2548877-A1 | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors | MSD Oss B.V. (NL) | 2013-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159810-A1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AND 4-IMIDAZOTRIAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS | BTK, ABL1, SYK | BTK 1/4885EGFR 822/4885ERBB2 40/4885 |
| US-20160151364-A1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AND 4-IMIDAZOTRIAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS | BTK, ABL1, SYK | BTK 1/4885EGFR 822/4885ERBB2 40/4885 |
| US-20140155385-A1 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AND 4-IMIDAZOTRIAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS | BTK, ABL1, SYK | BTK 1/4885EGFR 783/4885ERBB2 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.